The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies

Dane W. Burmeister, Emily H. Smith, Robert T. Cristel, Stephanie D. McKay, Huidong Shi, Gerald L. Arthur, Justin Wade Davis, Kristen H. Taylor

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

DNA methylation is an epigenetic modification that plays an important role in the regulation of gene expression. The function of RUNDC3B has yet to be determined, although its dysregulated expression has been associated with malignant potential of both breast and lung carcinoma. To elucidate the potential of using DNA methylation in RUNDC3B as a biomarker in lymphoid malignancies, the methylation status of six regions spanning the CpG island in the promoter region of RUNDC3B was determined in cancer cell lines. Lymphoid malignancies were found to have more prominent methylation and did not express RUNDC3B compared with myeloid malignancies and solid tumours, supporting the potential use of DNA methylation in this region as a biomarker for lymphoid malignancies. RUNDC3B contains a RUN domain in its N-terminal region that mediates interaction with Rap2, an important component of the mitogen-activated protein kinase (MAPK) cascade, which regulates cellular proliferation and differentiation. The protein sequence of RUNDC3B also contains characteristic binding sites for MAPK intermediates. Therefore, it is possible that RUNDC3B serves as a mediator between Rap2 and the MAPK signalling cascade. Three genes with MAPK-inducible expression were downregulated in a methylated leukaemia cell line (HSPA5, Jun and Fos). Jun and Fos combine to form the activating protein 1 transcription factor, and loss of this factor is associated with the dysregulation of genes involved in differentiation and proliferation. We hypothesize that the loss of RUNDC3B secondary to aberrant hypermethylation of the early growth response 3 transcription factor binding site results in dysregulated MAPK signalling and carcinogenesis in lymphoid malignancies.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalHematological Oncology
Volume35
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Methylation
Mitogen-Activated Protein Kinases
DNA Methylation
Neoplasms
Early Growth Response Protein 3
Activating Transcription Factor 1
Biomarkers
Binding Sites
Cell Line
CpG Islands
Gene Expression Regulation
Genetic Promoter Regions
Epigenomics
Genes
Carcinogenesis
Leukemia
Proteins
Down-Regulation
Cell Proliferation
Breast Neoplasms

Keywords

  • B cell
  • DNA methylation
  • Gene expression
  • Leukaemia
  • Lymphoma
  • RUNDC3B

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Burmeister, D. W., Smith, E. H., Cristel, R. T., McKay, S. D., Shi, H., Arthur, G. L., ... Taylor, K. H. (2017). The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies. Hematological Oncology, 35(1), 25-33. https://doi.org/10.1002/hon.2238

The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies. / Burmeister, Dane W.; Smith, Emily H.; Cristel, Robert T.; McKay, Stephanie D.; Shi, Huidong; Arthur, Gerald L.; Davis, Justin Wade; Taylor, Kristen H.

In: Hematological Oncology, Vol. 35, No. 1, 01.03.2017, p. 25-33.

Research output: Contribution to journalArticle

Burmeister, DW, Smith, EH, Cristel, RT, McKay, SD, Shi, H, Arthur, GL, Davis, JW & Taylor, KH 2017, 'The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies', Hematological Oncology, vol. 35, no. 1, pp. 25-33. https://doi.org/10.1002/hon.2238
Burmeister, Dane W. ; Smith, Emily H. ; Cristel, Robert T. ; McKay, Stephanie D. ; Shi, Huidong ; Arthur, Gerald L. ; Davis, Justin Wade ; Taylor, Kristen H. / The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies. In: Hematological Oncology. 2017 ; Vol. 35, No. 1. pp. 25-33.
@article{221ed64524a544b4a4a5bd3cb7a51267,
title = "The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies",
abstract = "DNA methylation is an epigenetic modification that plays an important role in the regulation of gene expression. The function of RUNDC3B has yet to be determined, although its dysregulated expression has been associated with malignant potential of both breast and lung carcinoma. To elucidate the potential of using DNA methylation in RUNDC3B as a biomarker in lymphoid malignancies, the methylation status of six regions spanning the CpG island in the promoter region of RUNDC3B was determined in cancer cell lines. Lymphoid malignancies were found to have more prominent methylation and did not express RUNDC3B compared with myeloid malignancies and solid tumours, supporting the potential use of DNA methylation in this region as a biomarker for lymphoid malignancies. RUNDC3B contains a RUN domain in its N-terminal region that mediates interaction with Rap2, an important component of the mitogen-activated protein kinase (MAPK) cascade, which regulates cellular proliferation and differentiation. The protein sequence of RUNDC3B also contains characteristic binding sites for MAPK intermediates. Therefore, it is possible that RUNDC3B serves as a mediator between Rap2 and the MAPK signalling cascade. Three genes with MAPK-inducible expression were downregulated in a methylated leukaemia cell line (HSPA5, Jun and Fos). Jun and Fos combine to form the activating protein 1 transcription factor, and loss of this factor is associated with the dysregulation of genes involved in differentiation and proliferation. We hypothesize that the loss of RUNDC3B secondary to aberrant hypermethylation of the early growth response 3 transcription factor binding site results in dysregulated MAPK signalling and carcinogenesis in lymphoid malignancies.",
keywords = "B cell, DNA methylation, Gene expression, Leukaemia, Lymphoma, RUNDC3B",
author = "Burmeister, {Dane W.} and Smith, {Emily H.} and Cristel, {Robert T.} and McKay, {Stephanie D.} and Huidong Shi and Arthur, {Gerald L.} and Davis, {Justin Wade} and Taylor, {Kristen H.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1002/hon.2238",
language = "English (US)",
volume = "35",
pages = "25--33",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - The expression of RUNDC3B is associated with promoter methylation in lymphoid malignancies

AU - Burmeister, Dane W.

AU - Smith, Emily H.

AU - Cristel, Robert T.

AU - McKay, Stephanie D.

AU - Shi, Huidong

AU - Arthur, Gerald L.

AU - Davis, Justin Wade

AU - Taylor, Kristen H.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - DNA methylation is an epigenetic modification that plays an important role in the regulation of gene expression. The function of RUNDC3B has yet to be determined, although its dysregulated expression has been associated with malignant potential of both breast and lung carcinoma. To elucidate the potential of using DNA methylation in RUNDC3B as a biomarker in lymphoid malignancies, the methylation status of six regions spanning the CpG island in the promoter region of RUNDC3B was determined in cancer cell lines. Lymphoid malignancies were found to have more prominent methylation and did not express RUNDC3B compared with myeloid malignancies and solid tumours, supporting the potential use of DNA methylation in this region as a biomarker for lymphoid malignancies. RUNDC3B contains a RUN domain in its N-terminal region that mediates interaction with Rap2, an important component of the mitogen-activated protein kinase (MAPK) cascade, which regulates cellular proliferation and differentiation. The protein sequence of RUNDC3B also contains characteristic binding sites for MAPK intermediates. Therefore, it is possible that RUNDC3B serves as a mediator between Rap2 and the MAPK signalling cascade. Three genes with MAPK-inducible expression were downregulated in a methylated leukaemia cell line (HSPA5, Jun and Fos). Jun and Fos combine to form the activating protein 1 transcription factor, and loss of this factor is associated with the dysregulation of genes involved in differentiation and proliferation. We hypothesize that the loss of RUNDC3B secondary to aberrant hypermethylation of the early growth response 3 transcription factor binding site results in dysregulated MAPK signalling and carcinogenesis in lymphoid malignancies.

AB - DNA methylation is an epigenetic modification that plays an important role in the regulation of gene expression. The function of RUNDC3B has yet to be determined, although its dysregulated expression has been associated with malignant potential of both breast and lung carcinoma. To elucidate the potential of using DNA methylation in RUNDC3B as a biomarker in lymphoid malignancies, the methylation status of six regions spanning the CpG island in the promoter region of RUNDC3B was determined in cancer cell lines. Lymphoid malignancies were found to have more prominent methylation and did not express RUNDC3B compared with myeloid malignancies and solid tumours, supporting the potential use of DNA methylation in this region as a biomarker for lymphoid malignancies. RUNDC3B contains a RUN domain in its N-terminal region that mediates interaction with Rap2, an important component of the mitogen-activated protein kinase (MAPK) cascade, which regulates cellular proliferation and differentiation. The protein sequence of RUNDC3B also contains characteristic binding sites for MAPK intermediates. Therefore, it is possible that RUNDC3B serves as a mediator between Rap2 and the MAPK signalling cascade. Three genes with MAPK-inducible expression were downregulated in a methylated leukaemia cell line (HSPA5, Jun and Fos). Jun and Fos combine to form the activating protein 1 transcription factor, and loss of this factor is associated with the dysregulation of genes involved in differentiation and proliferation. We hypothesize that the loss of RUNDC3B secondary to aberrant hypermethylation of the early growth response 3 transcription factor binding site results in dysregulated MAPK signalling and carcinogenesis in lymphoid malignancies.

KW - B cell

KW - DNA methylation

KW - Gene expression

KW - Leukaemia

KW - Lymphoma

KW - RUNDC3B

UR - http://www.scopus.com/inward/record.url?scp=84930146595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930146595&partnerID=8YFLogxK

U2 - 10.1002/hon.2238

DO - 10.1002/hon.2238

M3 - Article

C2 - 26011749

AN - SCOPUS:84930146595

VL - 35

SP - 25

EP - 33

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 1

ER -